ESTRO 2022 | PROMPTS trial: Using screening MRI to reduce incidence of clinical spinal cord compression in mCRPC
David Dearnaley, MA, MD, FRCP, FRCR, The Institute of Cancer Reseach and The Royal Marsden NHS Foundation Trust, London, UK, discusses the Phase III PROMPTS trial (ISRCTN: 74112318) which investigated the use of screening MRI and pre-emptive treatment in patients with castration resistant prostate cancer (CRPC) who also had asymptomatic spinal metastases, with the aim of reducing rates of clinical spinal cord compression (SCC). Patients were randomised to either the control arm, in which they received standard of care, or the experimental arm, in which they underwent a screening MRI scan. If the MRI showed no radiological SCC, patients continued on standard of care. If the MRI was positive, patients received pre-emptive treatment for the radiological SCC, followed by another MRI scan at 6 months. Prof. Dearnaley discusses the results of the trial, the implications of these results, and the possible future directions for this research. This interview took place at the European Society for Radiotherapy and Oncology (ESTRO) 2022 annual congress in Copenhagen, Denmark, and online.
Disclosures
Prof Dearnaley declares personal fees through the Rewards to Discoverer’s Scheme from The Institute of Cancer Research which receives royalty income from abiraterone, support from Cancer Research UK Program Grants C33589/A19727 “Advances in Physics for Precision Radiotherapy” and honoraria for advisory boards from Janssen. In addition, Prof Dearnaley has a patent EP1933709B1 issued for a localisation and stabilization device.
